美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Definium Therapeutics

36.82

-3.4300-8.52%

盤後：37.180.3600+0.98%19:58 EDT

成交量：452.69萬

成交額：1.70億

市值：49.47億

市盈率：-10.57

高：40.45

開：40.45

低：36.78

收：40.25

52周最高：49.70

52周最低：8.77

股本：1.34億

流通股本：1.31億

量比：1.71

換手率：3.45%

股息：- -

股息率：- -

每股收益(TTM):-3.4823

每股收益(LYR):-2.0600

淨資產收益率：-64.09%

總資產收益率：-20.64%

市淨率：5.39

市盈率(LYR):-17.87

資料載入中...

總覽公司新聞資訊公告

專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準

Definium Therapeutics股價盤前飆升20%，其LSD類抗焦慮藥物在第二項晚期研究中再次取得成功

Definium公司基於LSD的藥物在第二項成功的後期臨床研究中降低了焦慮水平

Definium Therapeutics：DT120口崩片III期全景研究在廣泛性焦慮障礙中達成主要及關鍵次要終點

Definium Therapeutics：DT120口腔崩解片100微克總體耐受性良好，安全性特徵一致，未現新型安全信號

Definium Therapeutics：DT120口崩片100微克在12周時顯示安慰劑校正的漢密爾頓焦慮量表評分降低5.1分

Definium Therapeutics將於2026年9月14日公布泛發性焦慮障礙III期Panorama研究的關鍵結果

Definium因抑鬱症藥物獲FDA「突破性療法」認定而股價上漲

Definium Therapeutics 重磅消息：DT120（麥角酸二乙胺）口崩片獲突破性療法認定，三期臨床數據亮眼

市場快訊——美股行情動態-Sutro Biopharma、Humacyte

Definium Therapeutics 焦慮症藥物晚期試驗達標，盤前股價飆升 22%

Definium Therapeutics股價上漲，因其治療焦慮症的藥物達到了後期臨床試驗的目標

Definium Therapeutics 宣佈DT120 Odt針對廣泛性焦慮障礙的3期Voyage研究取得積極頂線結果

Definium Therapeutics：DT120 Odt 三期Voyage研究達成主要及關鍵次要療效終點

Definium公司表示，基於LSD的藥片在晚期臨床試驗中可緩解焦慮

Definium Therapeutics：DT120 Odt 在研究中總體耐受性良好，未出現包括自殺傾向信號在內的新安全性信號

Definium Therapeutics：DT120 Odt 受試者漢密爾頓焦慮量表評分實現統計學顯著降低

美國研究綜述-德克爾斯品牌、羅林斯、聯合租賃

異動解讀｜Definium Therapeutics盤中上漲5.14%，報45.0美元

異動解讀｜Definium Therapeutics盤中上漲5.5%，DT120三期數據利好疊加行業併購催化

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/DFTX/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DFTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","market":"US","secType":"STK","nameCN":"Definium Therapeutics","latestPrice":36.82,"timestamp":1789502400000,"preClose":40.25,"halted":0,"volume":4526876,"hourTrading":{"tag":"盘后","latestPrice":37.18,"preClose":36.82,"latestTime":"19:58 EDT","volume":48449,"amount":1786475.1135,"timestamp":1789516731320,"change":0.36,"changeRate":0.009777,"amplitude":0.01711},"delay":0,"changeRate":-0.08521739130434781,"floatShares":131114280,"shares":134366950,"eps":-3.482311,"marketStatus":"已收盤","change":-3.43,"latestTime":"09-15 16:00:00 EDT","open":40.445,"high":40.445,"low":36.775,"amount":169838718.11286402,"amplitude":0.09118,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.482311,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789545600000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":40.25,"preHourTrading":{"tag":"盘前","latestPrice":40.21,"preClose":40.25,"latestTime":"09:29 EDT","volume":3384,"amount":136621.95112800002,"timestamp":1789478999999,"change":-0.04,"changeRate":-0.000994,"amplitude":0.017888},"postHourTrading":{"tag":"盘后","latestPrice":37.18,"preClose":36.82,"latestTime":"19:58 EDT","volume":48449,"amount":1786475.1135,"timestamp":1789516731320,"change":0.36,"changeRate":0.009777,"amplitude":0.01711},"volumeRatio":1.711397,"impliedVol":0.6873,"impliedVolPercentile":0.0241},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DFTX\",,,,,undefined,":{"symbol":"DFTX","floatShares":131114280,"roa":"-20.64%","roe":"-64.09%","lyrEps":-2.059999,"volumeRatio":1.711397,"shares":134366950,"dividePrice":0,"high":40.445,"amplitude":0.09118,"preClose":40.25,"low":36.775,"week52Low":8.7732,"pbRate":"5.39","week52High":49.7,"institutionHeld":0,"latestPrice":36.82,"eps":-3.482311,"divideRate":0,"volume":4526876,"delay":0,"ttmEps":-3.482311,"open":40.445,"prevYearClose":13.39,"prevWeekClose":38.89,"prevMonthClose":39.72,"prevQuarterClose":47.04,"fiveDayClose":38.23,"twentyDayClose":45.26,"sixtyDayClose":24.48},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DFTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"DFTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.55,"name":null,"time":"盤後","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"post","actualEps":-1.44},{"market":"US","date":"2026-05-07","symbol":"DFTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.47,"name":null,"time":"盤後","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"post","actualEps":-0.71},{"market":"US","date":"2026-02-26","symbol":"DFTX","fiscalQuarterEnding":"2025/12","expectedEps":-0.45,"name":null,"time":"盤後","type":"earning","dateTimestamp":1772082000000,"reportTimeType":"post","actualEps":-0.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DFTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DFTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3889,"buy":0.6111,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6111,"analysts":18,"updateTime":1787198400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DFTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DFTX","date":"2026-09-14","current":-10.603591,"percent":0.304878,"low":-27.074722,"twenty":-17.256702,"median":-11.216923,"eighty":-9.903787,"high":-8.802064,"avg":-13.938018,"sd":5.386259,"marketCap":5225530685},"quantilePoints":[{"date":"2026-01-16","current":-9.013032,"twenty":-8.970838,"median":-8.907548,"eighty":-8.844258,"marketCap":1515072711},{"date":"2026-01-23","current":-9.944809,"twenty":-9.944809,"median":-9.423248,"eighty":-8.819645,"marketCap":1671702464},{"date":"2026-01-30","current":-10.103035,"twenty":-10.103035,"median":-9.868626,"eighty":-9.013032,"marketCap":1698299969},{"date":"2026-02-06","current":-9.522872,"twenty":-10.196799,"median":-9.918438,"eighty":-9.522872,"marketCap":1600775783},{"date":"2026-02-13","current":-9.511152,"twenty":-10.179218,"median":-9.944809,"eighty":-9.522872,"marketCap":1598805598},{"date":"2026-02-20","current":-10.120616,"twenty":-10.18039,"median":-9.944809,"eighty":-9.520528,"marketCap":1701255248},{"date":"2026-02-27","current":-9.267085,"twenty":-10.187422,"median":-9.96239,"eighty":-9.520528,"marketCap":1703225433},{"date":"2026-03-06","current":-9.519961,"twenty":-10.18039,"median":-9.903787,"eighty":-9.502065,"marketCap":1749702163},{"date":"2026-03-13","current":-9.753213,"twenty":-10.18039,"median":-9.918437,"eighty":-9.518199,"marketCap":1792572359},{"date":"2026-03-20","current":-10.122078,"twenty":-10.169841,"median":-9.903787,"eighty":-9.52229,"marketCap":1860367087},{"date":"2026-03-27","current":-10.273963,"twenty":-10.169841,"median":-9.918437,"eighty":-9.559599,"marketCap":1888282563},{"date":"2026-04-02","current":-11.174427,"twenty":-10.181562,"median":-9.918437,"eighty":-9.550417,"marketCap":2053781457},{"date":"2026-04-10","current":-11.619234,"twenty":-10.247114,"median":-9.944809,"eighty":-9.57529,"marketCap":2135533923},{"date":"2026-04-17","current":-12.18338,"twenty":-10.396104,"median":-9.980506,"eighty":-9.589394,"marketCap":2239219977},{"date":"2026-04-24","current":-12.617338,"twenty":-11.167918,"median":-10.038572,"eighty":-9.618687,"marketCap":2318978480},{"date":"2026-05-01","current":-11.86876,"twenty":-11.389236,"median":-10.10442,"eighty":-9.643639,"marketCap":2181395062},{"date":"2026-05-08","current":-13.767387,"twenty":-11.71579,"median":-10.122078,"eighty":-9.665202,"marketCap":2530349365},{"date":"2026-05-15","current":-9.802755,"twenty":-11.643102,"median":-10.113211,"eighty":-9.689477,"marketCap":2328575817},{"date":"2026-05-22","current":-10.399644,"twenty":-11.570414,"median":-10.105791,"eighty":-9.636028,"marketCap":2470362634},{"date":"2026-05-29","current":-10.780735,"twenty":-11.483622,"median":-10.120616,"eighty":-9.642537,"marketCap":2560888064},{"date":"2026-06-05","current":-11.290386,"twenty":-11.393576,"median":-10.145827,"eighty":-9.660184,"marketCap":2681952193},{"date":"2026-06-12","current":-11.069996,"twenty":-11.344489,"median":-10.179218,"eighty":-9.68473,"marketCap":2629600138},{"date":"2026-06-18","current":-11.216923,"twenty":-11.349156,"median":-10.196799,"eighty":-9.702279,"marketCap":2664501508},{"date":"2026-06-26","current":-20.565124,"twenty":-11.510745,"median":-10.247973,"eighty":-9.723056,"marketCap":4885101210},{"date":"2026-07-02","current":-24.252692,"twenty":-11.77112,"median":-10.299843,"eighty":-9.753213,"marketCap":5761057223},{"date":"2026-07-10","current":-27.074722,"twenty":-12.069466,"median":-10.333633,"eighty":-9.796609,"marketCap":6431410656},{"date":"2026-07-17","current":-24.643864,"twenty":-12.519698,"median":-10.492938,"eighty":-9.802755,"marketCap":5853977501},{"date":"2026-07-24","current":-23.990048,"twenty":-12.931958,"median":-10.537388,"eighty":-9.812883,"marketCap":5698667894},{"date":"2026-07-31","current":-24.861803,"twenty":-14.440728,"median":-10.67054,"eighty":-9.817222,"marketCap":5905747370},{"date":"2026-08-07","current":-17.312135,"twenty":-19.588062,"median":-10.789918,"eighty":-9.824231,"marketCap":6124773739},{"date":"2026-08-14","current":-16.673146,"twenty":-17.887875,"median":-10.831241,"eighty":-9.831914,"marketCap":5898709105},{"date":"2026-08-21","current":-17.242844,"twenty":-17.526933,"median":-11.058518,"eighty":-9.861594,"marketCap":6100259530},{"date":"2026-08-28","current":-16.642763,"twenty":-17.426666,"median":-11.092954,"eighty":-9.887379,"marketCap":5887959749},{"date":"2026-09-04","current":-14.432336,"twenty":-17.33018,"median":-11.139168,"eighty":-9.901443,"marketCap":5105944100},{"date":"2026-09-11","current":-14.329791,"twenty":-17.27056,"median":-11.195675,"eighty":-9.903787,"marketCap":5069665023},{"date":"2026-09-14","current":-14.770357,"twenty":-17.256702,"median":-11.216923,"eighty":-9.903787,"marketCap":5225530685}],"updateTime":1789492658343},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DFTX\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667962699","title":"專家敦促美國食品藥品監督管理局（FDA）為迷幻藥物制定明確的安全和獲取標準","url":"https://stock-news.laohu8.com/highlight/detail?id=2667962699","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667962699?lang=zh_tw&edition=fundamental","pubTime":"2026-09-15 06:39","pubTimestamp":1789425555,"startTime":"0","endTime":"0","summary":"此次听证会是美国总统唐纳德·特朗普政府自4月  以来，为推动合格的迷幻药物项目  进入市场所开展的、历时数月的最新举措。发言者敦促研究人员收集有关月经周期、妊娠及产后状况、围绝经期、绝经期、激素水平及合并用药的数据，并警告称汇总结果可能会掩盖疗效或不良事件方面的差异。“FDA对安全性和有效性的评估……必须始终是未来任何临床应用的基础，”美国精神病学协会表示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4561NY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX","PSIL","BK4139","CMPS","GHRS","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145365920","title":"Definium Therapeutics股價盤前飆升20%，其LSD類抗焦慮藥物在第二項晚期研究中再次取得成功","url":"https://stock-news.laohu8.com/highlight/detail?id=1145365920","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145365920?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:33","pubTimestamp":1789385589,"startTime":"0","endTime":"0","summary":"Definium Therapeutics的股价在盘前交易中大幅上涨20%，这一跃升的背后，是该公司基于LSD研发的抗焦虑药物在第二项关键性后期临床试验中再次交出了积极答卷。此番捷报频传，无疑为市场注入了强心剂，投资者信心随之显著提振。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667650759","title":"Definium公司基於LSD的藥物在第二項成功的後期臨床研究中降低了焦慮水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2667650759","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667650759?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:00","pubTimestamp":1789383636,"startTime":"0","endTime":"0","summary":"Definium公司基于LSD的药物在第二项成功的后期临床研究中降低了焦虑水平Kamal Choudhury/Puyaan Singh9月14日-Definium Therapeutics公司周一表示，其基于LSD的治疗方法在临床试验中减轻了广泛性焦虑障碍的症状，这使该公司针对该病症的晚期临床研究第二次取得成功。监管机构 和 投资者对迷幻类疗法的热情，推动 Definium 股价今年上涨近三倍。Definium称，疗效最早在治疗第二天就显现，并持续至第12周。Definium预计将于2027年上半年向美国食品药品监督管理局提交上市申请。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nL4S4560QM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174385904","title":"Definium Therapeutics：DT120口崩片III期全景研究在廣泛性焦慮障礙中達成主要及關鍵次要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1174385904","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174385904?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:00","pubTimestamp":1789383614,"startTime":"0","endTime":"0","summary":"Definium Therapeutics今日宣布，其评估DT120口崩片治疗广泛性焦虑障碍的III期PANORAMA研究，已成功达到主要终点及关键次要终点。这一里程碑式的成果，为该公司在焦虑症治疗领域的布局注入了强劲动力。Definium Therapeutics表示，详细的完整研究数据将在即将召开的医学会议上进行展示，并计划基于这些发现，积极与美国食品药品监督管理局等监管机构沟通，推进该药物的注册上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107633829","title":"Definium Therapeutics：DT120口腔崩解片100微克總體耐受性良好，安全性特徵一致，未現新型安全信號","url":"https://stock-news.laohu8.com/highlight/detail?id=1107633829","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107633829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:00","pubTimestamp":1789383611,"startTime":"0","endTime":"0","summary":"Definium Therapeutics近日公布，其研发的DT120口腔崩解片在100微克剂量下展现出总体良好的耐受性。值得注意的是，该药物的安全性特征保持高度一致性，且未出现任何新型安全信号。在临床观察中，受试者对DT120 Odt 100 Mcg的接受度令人鼓舞。Definium Therapeutics的这项发现，不仅印证了该候选药物的潜在价值，同时也为后续更深入的临床研究奠定了坚实基础。安全性特征的一致性，往往意味着更高的可预测性和更低的开发风险。眼下，公司正积极推进该药物的进一步评估工作。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148441427","title":"Definium Therapeutics：DT120口崩片100微克在12周時顯示安慰劑校正的漢密爾頓焦慮量表評分降低5.1分","url":"https://stock-news.laohu8.com/highlight/detail?id=1148441427","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148441427?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 19:00","pubTimestamp":1789383609,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其候选药物DT120口崩片（Odt）在100微克剂量下，于治疗第12周时展现出了显著的抗焦虑疗效。具体数据显示，与安慰剂相比，该药物使患者的汉密尔顿焦虑量表评分平均降低了5.1分，这一结果具有临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160872994","title":"Definium Therapeutics將於2026年9月14日公布泛發性焦慮障礙III期Panorama研究的關鍵結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1160872994","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160872994?lang=zh_tw&edition=fundamental","pubTime":"2026-09-14 05:00","pubTimestamp":1789333236,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，计划于2026年9月14日召开会议，重点讨论其在泛发性焦虑障碍（GAD）领域所进行的III期Panorama研究的顶线结果。这一备受关注的数据发布，将为该候选疗法的疗效与安全性提供关键性证据。公司方面表示，此次披露的结果有望为后续的监管申报及临床开发路径奠定坚实基础。业界普遍预期，这一研究数据不仅关乎Definium自身的管线价值，也可能对整个焦虑障碍治疗领域产生深远影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665375780","title":"Definium因抑鬱症藥物獲FDA「突破性療法」認定而股價上漲","url":"https://stock-news.laohu8.com/highlight/detail?id=2665375780","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665375780?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:59","pubTimestamp":1788875957,"startTime":"0","endTime":"0","summary":"BUZZ-Definium因抑郁症药物获FDA“突破性疗法”认定而股价上涨9月8日-** Definium Therapeutics（DFTX.O）股价上涨2.2%，至38.92美元** 该公司表示，其基于LSD的实验性药丸DT120 (link) 获得美国食品药品监督管理局（FDA）授予的突破性疗法认定，用于治疗重度抑郁症（MDD）** “突破性疗法”认定旨在加速针对严重疾病或存在未满足医疗需求","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nL4T45014Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168482991","title":"Definium Therapeutics 重磅消息：DT120（麥角酸二乙胺）口崩片獲突破性療法認定，三期臨床數據亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=1168482991","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168482991?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:01","pubTimestamp":1788865279,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 迎来重大里程碑——该公司研发的 DT120口腔崩解片，在针对重度抑郁症的治疗中取得积极三期临床试验结果后，成功获得美国食品药品监督管理局授予的突破性疗法认定。突破性疗法认定是FDA为加速严重或危及生命疾病的药物研发与审查而设立的特别通道，旨在确保患者能够尽快获得有前景的新疗法。展望未来，Definium Therapeutics 将有望凭借这一认定的政策优势，与FDA展开更密切的沟通协作，力求大幅缩短药物从研发到上市的时间周期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659909279","title":"市場快訊——美股行情動態-Sutro Biopharma、Humacyte","url":"https://stock-news.laohu8.com/highlight/detail?id=2659909279","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659909279?lang=zh_tw&edition=fundamental","pubTime":"2026-08-13 00:18","pubTimestamp":1786551516,"startTime":"0","endTime":"0","summary":".N美国东部时间11:30，道琼斯工业平均指数.DJI持平于53,793.87点。标普500指数.SPX上涨0.22%，报7,745.57点；纳斯达克综合指数.IXIC上涨0.47%，报26,569.32点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4T4491DW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BETA","WXM","CRWV","GAP","HUMA","SRHR","EROC","CHTR","SLN","FSLR","LQDA","DPRE","NBIL","NBIS","FRNW","TECH","NBIX","CIEN","TRMB","PFGC","HRB","LITE","SLXN","SMMT","ALT","ABSI","NTHI","EAT","STRO","CAVA","LITX","DFTX","OPLN","BIVI","RSPG","ANNX","SLNCF","OFAL","LOCL","NCMI","SMWB","LAZR","O","TPL","UFO","UAMY","SVV","LUMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192985516","title":"Definium Therapeutics 焦慮症藥物晚期試驗達標，盤前股價飆升 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1192985516","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192985516?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:45","pubTimestamp":1786535108,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 的股价在盘前交易时段猛涨22%，原因在于该公司针对焦虑症的一款药物成功达成了后期临床试验的核心目标。这一喜讯瞬间点燃了市场热情，投资者纷纷涌入，推动股价大幅上扬。此次试验结果无疑为这家生物技术公司注入了强劲的发展动力，也为其在精神健康领域的布局增添了关键砝码。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658744709","title":"Definium Therapeutics股價上漲，因其治療焦慮症的藥物達到了後期臨床試驗的目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2658744709","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658744709?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:43","pubTimestamp":1786535004,"startTime":"0","endTime":"0","summary":"BUZZ-Definium Therapeutics股价上涨，因其治疗焦虑症的药物达到了后期临床试验的目标8月12日-** 生物技术公司 Definium Therapeutics（DFTX.O）的股价在盘前交易中上涨 22.2%，至 50.01 美元** 该公司 (link) 表示，在一项晚期临床研究中，其基于LSD的实验性口服药显著减轻了广泛性焦虑障碍（GAD）成年患者的焦虑症状，达到了试验的","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4S4490US:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["600776","BK0028","BK0012","BK0214","BK4007","BK0188","BK0123","BK0167","DFTX","BK0010","BK0090"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143492874","title":"Definium Therapeutics 宣佈DT120 Odt針對廣泛性焦慮障礙的3期Voyage研究取得積極頂線結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1143492874","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143492874?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:01","pubTimestamp":1786532478,"startTime":"0","endTime":"0","summary":"Definium Therapeutics（DFTX）今日发布重磅消息：其针对广泛性焦虑障碍的DT120 Odt，在3期Voyage研究中录得积极的顶线数据。该研究结果令人振奋，为这款在研疗法带来了新曙光。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168532165","title":"Definium Therapeutics：DT120 Odt 三期Voyage研究達成主要及關鍵次要療效終點","url":"https://stock-news.laohu8.com/highlight/detail?id=1168532165","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168532165?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:01","pubTimestamp":1786532471,"startTime":"0","endTime":"0","summary":"Definium Therapeutics宣布，其关键药物DT120 Odt的三期临床试验Voyage研究已成功达成主要及关键次要疗效终点。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658971366","title":"Definium公司表示，基於LSD的藥片在晚期臨床試驗中可緩解焦慮","url":"https://stock-news.laohu8.com/highlight/detail?id=2658971366","media":"路透中文","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658971366?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532446,"startTime":"0","endTime":"0","summary":"Definium公司表示，基于LSD的药片在晚期临床试验中可缓解焦虑路透8月12日-Definium Therapeutics公司周三表示，其基于LSD的实验性药片在一项晚期研究中显著减轻了焦虑症状，达到了试验的主要目标。该公司表示，经安慰剂校正后的5.4分差异在统计学上显著且具有临床意义。监管机构 以及投资者对迷幻类疗法的热情 ，推动Definium股价今年迄今已上涨逾三倍。此次试验是Definium公司针对DT120取得的第二项晚期临床试验成功，此前该公司在6月公布了一项抑郁症研究的积极结果 。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260812:nL4T4490RK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103074392","title":"Definium Therapeutics：DT120 Odt 在研究中總體耐受性良好，未出現包括自殺傾向信號在內的新安全性信號","url":"https://stock-news.laohu8.com/highlight/detail?id=1103074392","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103074392?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532410,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 宣布，其药物 DT120 Odt 在一项临床研究中展现出总体良好的耐受性。研究未发现任何新的安全性信号，其中尤为关键的是，没有监测到自杀倾向相关的信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159415209","title":"Definium Therapeutics：DT120 Odt 受試者漢密爾頓焦慮量表評分實現統計學顯著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1159415209","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159415209?lang=zh_tw&edition=fundamental","pubTime":"2026-08-12 19:00","pubTimestamp":1786532409,"startTime":"0","endTime":"0","summary":"Definium Therapeutics 宣布，其药物 DT120 Odt 在临床试验中取得突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653704896","title":"美國研究綜述-德克爾斯品牌、羅林斯、聯合租賃","url":"https://stock-news.laohu8.com/highlight/detail?id=2653704896","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653704896?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 15:16","pubTimestamp":1784877371,"startTime":"0","endTime":"0","summary":"美国研究综述-德克尔斯品牌、罗林斯、联合租赁路透7月24日-周五，华尔街证券分析师修订了多家在美国上市公司的评级和目标价，其中包括德克斯品牌、罗林斯和联合租赁。股票按字母顺序排列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4S43Q0I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBWM","CNAV","BMED","IDEF","TEK","AAL","PSCH","NVR","DECK","CTSH","LMT","DAMD","CMCSA","THRM","DOMO","ACI","DFTX","AMAT","LRCX","URI","FCNCA","AMP","ROL","AMDL","LOB","PNFP","DOV","EW","PKG","BX","ALK","BPOP","MPLT","AMD","DOW","NIC","FCXG","MEDP","INTC","R","FOA","HON","NSC","KRMN","SAM","OBK","JUP.UK","FCX","MOH","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133954038","title":"異動解讀｜Definium Therapeutics盤中上漲5.14%，報45.0美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133954038","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133954038?lang=zh_tw&edition=fundamental","pubTime":"2026-07-22 03:49","pubTimestamp":1784663380,"startTime":"0","endTime":"0","summary":"7月22日，Definium Therapeutics盘中上涨5.14%，报45.0美元/股，成交额3936.95万美元。Definium Therapeutics所在的制药行业中，个股中，礼来涨1.95%，强生涨0.65%，默沙东涨1.46%，惠普森医药涨853.85%，辉瑞涨0.63%。Definium Therapeutics是一家处于后期阶段的临床生物制药公司，正在开发新的候选产品来治疗大脑健康障碍。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105069526","title":"異動解讀｜Definium Therapeutics盤中上漲5.5%，DT120三期數據利好疊加行業併購催化","url":"https://stock-news.laohu8.com/highlight/detail?id=1105069526","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105069526?lang=zh_tw&edition=fundamental","pubTime":"2026-07-16 21:42","pubTimestamp":1784209375,"startTime":"0","endTime":"0","summary":"7月16日，Definium Therapeutics盘中上涨5.5%，报46.68美元/股，成交额2316.68万美元。消息面上，公司核心候选药物DT120口崩片治疗重度抑郁症的3期EMERGE研究此前取得积极顶线结果，主要终点及所有关键次要疗效终点均达成。随后公司成功完成8.05亿美元增发募资，承销商全额行使超额配售权。RBC Capital将目标价从36美元大幅上调至57美元，维持\"跑赢大盘\"评级，当前股价仍低于该目标价。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Definium Therapeutics盘中上涨5.5%，DT120三期数据利好叠加行业并购催化","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DFTX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":55,"code":"91000000","status":"200"}]}}